Novel serum glycan monosaccharide composite-based biomarkers for colorectal cancer (CRC) and colorectal adenoma (CRA)

A group from Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China, etc. has developed novel serum glycan monosaccharide composite-based biomarkers for colorectal cancer (CRC) and colorectal adenoma (CRA).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099097/

HPAEC-PAD method was used to quantify the concentrations of two free monosaccharides (Glc-F and Man-F) and the six hydrolyzed monosaccharides (Fuc-H, GalN-H, GlcN-H, Gal-H, Glc-H, and Man-H) in the sera of healthy individuals, CRA, and CRC patients.
The concentrations of monosaccharides in serum were significantly higher in CRA and CRC patients than in healthy individuals. In concreat, concentrations of Fuc-H, GalN-H, GlcN-H, Gal-H, Glc-H, and Man-H in serum were significantly higher in CRC patients compared with healthy individuals. In addition, concentrations of Fuc-H, Gal-H, Glc-H, and Man-H in serum were significantly higher in CRA patients than healthy individuals

The logistic regression analysis was used to develop diagnostic models based on the above results. Tow types of the models were developed, one is MC1 and the other is MC2.
The logistic regression equation for MC1 was as follows: MC1 = -8.18 – 0.021 Fuc-H – 0.004 GlcN-H + 0.011 Man-H, where the Fuc-H, GlcN-H and Man-H were in μmol/L, and
the logistic regression equation for MC2 was as follows: MC2= -6.639 – 0.022 Fuc-H + 0.003 Gal-H + 0.003 Man-H, where the Fuc-H, Gal-H and Man-H were in μmol/L

MC1 was used to distinguish between healthy individuals and CRC, and MC2 was used to distinguish between healthy individuals and CRA. Area under receptor operating characteristic curve (AUC) of MC2 and MC1 was 0.8025 and 0.9403 respectively.
As a reference, the AUC of the existence marker CEA between healthy individuals and CRC was 0.7384.